Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:pyrrolopyrimidine
go back to main search page
Accession:CHEBI:38670 term browser browse the term
Synonyms:related_synonym: pyrrolopyrimidines


show annotations for term's descendants           Sort by:
 
5-iodotubercidin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cdkn1b cyclin-dependent kinase inhibitor 1B decreases phosphorylation EXP 5-iodotubercidin results in decreased phosphorylation of CDKN1B protein CTD PMID:26953159 NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
JBrowse link
G Clk1 CDC-like kinase 1 decreases activity ISO 5-iodotubercidin results in decreased activity of CLK1 protein CTD PMID:26953159 NCBI chr 9:65,296,777...65,308,017
Ensembl chr 9:65,296,778...65,307,995
JBrowse link
G Clk2 CDC-like kinase 2 decreases activity ISO 5-iodotubercidin results in decreased activity of CLK2 protein CTD PMID:26953159 NCBI chr 2:188,476,789...188,488,809
Ensembl chr 2:188,476,820...188,496,191
JBrowse link
G Clk3 CDC-like kinase 3 decreases activity ISO 5-iodotubercidin results in decreased activity of CLK3 protein CTD PMID:26953159 NCBI chr 8:62,528,135...62,543,550
Ensembl chr 8:62,528,225...62,542,622
JBrowse link
G Clk4 CDC-like kinase 4 decreases activity ISO 5-iodotubercidin results in decreased activity of CLK4 protein CTD PMID:26953159 NCBI chr10:36,715,565...36,733,473
Ensembl chr10:36,715,565...36,733,133
JBrowse link
G Dyrk1a dual specificity tyrosine phosphorylation regulated kinase 1A decreases activity ISO 5-iodotubercidin results in decreased activity of DYRK1A protein CTD PMID:26953159 NCBI chr11:34,858,339...34,958,733
Ensembl chr11:34,865,532...34,956,536
JBrowse link
G Dyrk1b dual specificity tyrosine phosphorylation regulated kinase 1B decreases activity ISO 5-iodotubercidin results in decreased activity of DYRK1B protein CTD PMID:26953159 NCBI chr 1:85,112,819...85,120,840
Ensembl chr 1:85,112,247...85,120,839
JBrowse link
G Dyrk2 dual specificity tyrosine phosphorylation regulated kinase 2 decreases activity ISO 5-iodotubercidin results in decreased activity of DYRK2 protein CTD PMID:26953159 NCBI chr 7:61,785,423...61,816,775
Ensembl chr 7:61,786,309...61,798,729
JBrowse link
G Dyrk3 dual specificity tyrosine phosphorylation regulated kinase 3 decreases activity ISO 5-iodotubercidin results in decreased activity of DYRK3 protein CTD PMID:26953159 NCBI chr13:47,906,230...47,916,877
Ensembl chr13:47,906,231...47,916,877
JBrowse link
G Dyrk4 dual specificity tyrosine phosphorylation regulated kinase 4 decreases activity ISO 5-iodotubercidin results in decreased activity of DYRK4 protein CTD PMID:26953159 NCBI chr 4:159,426,447...159,467,973
Ensembl chr 4:159,427,340...159,467,955
JBrowse link
G Ins2 insulin 2 increases secretion
affects secretion
ISO 5-iodotubercidin results in increased secretion of INS protein
5-iodotubercidin affects the secretion of INS protein
CTD PMID:26953159 NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034
JBrowse link
G Mmp3 matrix metallopeptidase 3 increases expression ISO 5-iodotubercidin results in increased expression of MMP3 mRNA CTD PMID:26953159 NCBI chr 8:5,676,608...5,698,579
Ensembl chr 8:5,676,665...5,698,579
JBrowse link
G Nefm neurofilament medium increases expression ISO 5-iodotubercidin results in increased expression of NEFM mRNA CTD PMID:26953159 NCBI chr15:44,855,307...44,860,604
Ensembl chr15:44,855,310...44,860,604
JBrowse link
G Olfm4 olfactomedin 4 decreases expression ISO 5-iodotubercidin results in decreased expression of OLFM4 mRNA CTD PMID:26953159 NCBI chr15:62,384,263...62,429,450
Ensembl chr15:62,406,873...62,429,449
JBrowse link
G Reg3b regenerating family member 3 beta decreases expression ISO 5-iodotubercidin results in decreased expression of REG3A mRNA CTD PMID:26953159 NCBI chr 4:109,467,272...109,470,510
Ensembl chr 4:109,467,272...109,470,510
JBrowse link
G Slc2a2 solute carrier family 2 member 2 increases expression ISO 5-iodotubercidin results in increased expression of SLC2A2 mRNA CTD PMID:26953159 NCBI chr 2:114,413,427...114,445,418
Ensembl chr 2:114,413,410...114,445,395
JBrowse link
antalarmin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Crhr1 corticotropin releasing hormone receptor 1 multiple interactions ISO antalarmin binds to and results in decreased activity of CRHR1 protein CTD PMID:16014403 NCBI chr10:92,191,473...92,233,662
Ensembl chr10:92,191,718...92,232,645
JBrowse link
G Cyp11a1 cytochrome P450, family 11, subfamily a, polypeptide 1 decreases expression ISO antalarmin results in decreased expression of CYP11A1 mRNA CTD PMID:16014403 NCBI chr 8:62,798,317...62,809,848
Ensembl chr 8:62,779,875...62,809,893
JBrowse link
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 decreases expression ISO antalarmin results in decreased expression of CYP17A1 mRNA CTD PMID:16014403 NCBI chr 1:266,422,127...266,429,947
Ensembl chr 1:266,422,132...266,428,239
JBrowse link
G Faah fatty acid amide hydrolase multiple interactions EXP antalarmin inhibits the reaction [Corticosterone results in increased activity of FAAH protein] CTD PMID:26821211 NCBI chr 5:134,852,899...134,872,095
Ensembl chr 5:134,852,875...134,871,775
JBrowse link
G Star steroidogenic acute regulatory protein decreases expression ISO antalarmin results in decreased expression of STAR mRNA CTD PMID:16014403 NCBI chr16:71,036,204...71,040,847
Ensembl chr16:71,036,204...71,040,847
JBrowse link
G Sult2a1 sulfotransferase family 2A member 1 decreases expression ISO antalarmin results in decreased expression of SULT2A1 mRNA CTD PMID:16014403 NCBI chr 1:76,558,721...76,614,315
Ensembl chr 1:76,252,329...76,780,230
JBrowse link
GSK2656157 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Atf4 activating transcription factor 4 multiple interactions ISO GSK2656157 inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA]; GSK2656157 inhibits the reaction [perfluorooctanoic acid results in increased expression of ATF4 protein]; GSK2656157 inhibits the reaction [Thapsigargin results in increased expression of ATF4 protein] CTD PMID:30602124, PMID:32578922 NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2 subunit alpha multiple interactions ISO GSK2656157 inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein] CTD PMID:30602124 NCBI chr 6:102,048,372...102,073,041
Ensembl chr 6:102,048,372...102,073,041
JBrowse link
G Ostn osteocrin multiple interactions ISO GSK2656157 inhibits the reaction [Glucosamine results in increased expression of OSTN mRNA] CTD PMID:30602124 NCBI chr11:76,851,923...76,888,140
Ensembl chr11:76,851,322...76,888,178
JBrowse link
pemetrexed term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc5 ATP binding cassette subfamily C member 5 decreases response to substance ISO ABCC5 protein results in decreased susceptibility to Pemetrexed CTD PMID:15897250 NCBI chr11:84,395,982...84,490,215
Ensembl chr11:84,396,033...84,490,211
JBrowse link
G Alk ALK receptor tyrosine kinase affects response to substance ISO ALK gene mutant form affects the susceptibility to Pemetrexed CTD PMID:21336183 NCBI chr 6:22,696,415...23,203,791
Ensembl chr 6:22,696,397...23,203,775
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO [Cisplatin co-treated with Pemetrexed co-treated with Valproic Acid] results in decreased expression of BCL2 protein; [Cisplatin co-treated with Pemetrexed co-treated with Vorinostat] results in decreased expression of BCL2 protein CTD PMID:19351772 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions ISO [Cisplatin co-treated with Pemetrexed] results in increased cleavage of BID protein CTD PMID:19351772 NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203
JBrowse link
G C3 complement C3 multiple interactions ISO [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of C3 mRNA; [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of C3 protein CTD PMID:22975265 NCBI chr 9:9,721,137...9,747,084
Ensembl chr 9:9,721,105...9,747,167
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions ISO [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of CCL2 mRNA CTD PMID:22975265 NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO [Cisplatin co-treated with Pemetrexed co-treated with Valproic Acid] results in decreased expression of CCND1 protein; [Cisplatin co-treated with Pemetrexed co-treated with vorinostat] results in decreased expression of CCND1 protein CTD PMID:19351772 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions ISO [Cisplatin co-treated with Pemetrexed co-treated with Valproic Acid] results in increased expression of CDKN1A protein; [Cisplatin co-treated with Pemetrexed co-treated with vorinostat] results in increased expression of CDKN1A protein; [Cisplatin co-treated with Pemetrexed] results in increased expression of CDKN1A protein CTD PMID:19351772 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator decreases response to substance ISO CFLAR results in decreased susceptibility to Pemetrexed CTD PMID:21726997 NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO DDIT3 mutant form inhibits the reaction [Pemetrexed results in increased expression of TNFRSF10B] CTD PMID:21726997 NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
JBrowse link
G Dhfr dihydrofolate reductase multiple interactions ISO [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of DHFR mRNA CTD PMID:22975265 NCBI chr 2:21,931,887...21,958,927
Ensembl chr 2:21,931,493...21,962,453
JBrowse link
G Ercc1 ERCC excision repair 1, endonuclease non-catalytic subunit multiple interactions
decreases expression
ISO Pemetrexed inhibits the reaction [resveratrol results in increased stability of and results in increased expression of ERCC1 mRNA]; Pemetrexed inhibits the reaction [resveratrol results in increased stability of and results in increased expression of ERCC1 protein]
Pemetrexed results in decreased expression of ERCC1 mRNA; Pemetrexed results in decreased expression of ERCC1 protein
CTD PMID:23912706 NCBI chr 1:80,256,973...80,268,198
Ensembl chr 1:80,256,973...80,268,198
JBrowse link
G Fas Fas cell surface death receptor increases expression
multiple interactions
ISO Pemetrexed results in increased expression of FAS protein
TP53 protein affects the reaction [Pemetrexed results in increased expression of FAS protein]; TYMS protein inhibits the reaction [Pemetrexed results in increased expression of FAS protein]
CTD PMID:15161716 NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
JBrowse link
G Fpgs folylpolyglutamate synthase increases response to substance ISO FPGS protein results in increased susceptibility to Pemetrexed CTD PMID:17575230 NCBI chr 3:11,717,667...11,729,694
Ensembl chr 3:11,717,667...11,723,327
JBrowse link
G Ggh gamma-glutamyl hydrolase affects response to substance ISO GGH protein affects the susceptibility to Pemetrexed CTD PMID:17575230 NCBI chr 5:34,040,258...34,063,369
Ensembl chr 5:34,040,258...34,063,361
JBrowse link
G Ifi30 IFI30, lysosomal thiol reductase multiple interactions ISO [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IFI30 mRNA CTD PMID:22975265 NCBI chr16:20,426,566...20,430,772
Ensembl chr16:20,426,566...20,430,752
JBrowse link
G Il11 interleukin 11 multiple interactions ISO [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL11 mRNA CTD PMID:22975265 NCBI chr 1:72,636,959...72,643,255
Ensembl chr 1:72,635,267...72,643,255
JBrowse link
G Il13ra2 interleukin 13 receptor subunit alpha 2 multiple interactions ISO [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL13RA2 mRNA CTD PMID:22975265 NCBI chr  X:118,443,955...118,514,716
Ensembl chr  X:118,443,823...118,513,061
JBrowse link
G Il1a interleukin 1 alpha multiple interactions ISO [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL1A mRNA CTD PMID:22975265 NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
JBrowse link
G Il1rl1 interleukin 1 receptor-like 1 multiple interactions ISO [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL1RL1 mRNA CTD PMID:22975265 NCBI chr 9:47,133,483...47,184,316
Ensembl chr 9:47,134,034...47,182,170
JBrowse link
G Il33 interleukin 33 multiple interactions ISO [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL33 mRNA CTD PMID:22975265 NCBI chr 1:248,112,611...248,147,030
Ensembl chr 1:248,132,090...248,147,029
JBrowse link
G Il7r interleukin 7 receptor multiple interactions ISO [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL7R mRNA CTD PMID:22975265
G Klrc1 killer cell lectin like receptor C1 multiple interactions ISO [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of KLRC1 mRNA CTD PMID:22975265 NCBI chr 4:163,453,435...163,463,718
Ensembl chr 4:163,458,528...163,463,718
JBrowse link
G Kras KRAS proto-oncogene, GTPase decreases expression
increases response to substance
ISO Pemetrexed results in decreased expression of KRAS mRNA; Pemetrexed results in decreased expression of KRAS mRNA mutant form; Pemetrexed results in decreased expression of KRAS protein
KRAS gene mutant form results in increased susceptibility to Pemetrexed
CTD PMID:24688052 NCBI chr 4:179,482,562...179,515,483
Ensembl chr 4:179,486,105...179,515,558
JBrowse link
G Mthfd2 methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase increases response to substance ISO MTHFD2 protein results in increased susceptibility to Pemetrexed CTD PMID:24688052 NCBI chr 4:115,004,433...115,015,965
Ensembl chr 4:115,004,448...115,015,965
JBrowse link
G Npm1 nucleophosmin 1 decreases response to substance ISO NPM1 protein results in decreased susceptibility to Pemetrexed CTD PMID:24736981 NCBI chr10:18,080,949...18,091,062
Ensembl chr10:18,080,950...18,090,950
JBrowse link
G Nras NRAS proto-oncogene, GTPase increases response to substance ISO NRAS gene mutant form results in increased susceptibility to Pemetrexed CTD PMID:24688052 NCBI chr 2:205,553,119...205,563,716
Ensembl chr 2:205,553,163...205,560,791
JBrowse link
G Rbm17 RNA binding motif protein 17 decreases response to substance ISO RBM17 protein results in decreased susceptibility to Pemetrexed CTD PMID:16061639 NCBI chr17:70,586,345...70,603,289
Ensembl chr17:70,586,394...70,603,267
JBrowse link
G Slc19a1 solute carrier family 19 member 1 multiple interactions
increases response to substance
ISO Pemetrexed inhibits the reaction [SLC19A1 protein results in increased transport of Methotrexate]
SLC19A1 exon mutant form results in increased susceptibility to Pemetrexed
CTD PMID:16505119, PMID:21879757 NCBI chr20:12,334,675...12,354,517
Ensembl chr20:12,334,676...12,352,377
JBrowse link
G Slc46a1 solute carrier family 46 member 1 multiple interactions
increases activity
increases response to substance
ISO Pemetrexed inhibits the reaction [SLC46A1 protein results in increased uptake of Methotrexate]
Pemetrexed results in increased activity of SLC46A1 protein
SLC46A1 protein results in increased susceptibility to Pemetrexed
CTD PMID:21879757 NCBI chr10:65,728,508...65,741,708
Ensembl chr10:65,733,991...65,740,828
JBrowse link
G Tnfaip3 TNF alpha induced protein 3 multiple interactions ISO [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of TNFAIP3 mRNA CTD PMID:22975265 NCBI chr 1:14,401,103...14,416,369
Ensembl chr 1:14,402,913...14,412,807
JBrowse link
G Tnfrsf9 TNF receptor superfamily member 9 multiple interactions ISO [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of TNFRSF9 mRNA CTD PMID:22975265 NCBI chr 5:168,009,245...168,035,813
Ensembl chr 5:168,009,393...168,035,810
JBrowse link
G Tp53 tumor protein p53 multiple interactions
affects response to substance
ISO TP53 protein affects the reaction [Pemetrexed results in increased expression of FAS protein]
TP53 protein affects the susceptibility to Pemetrexed
CTD PMID:15161716, PMID:17339891 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
G Traf1 TNF receptor-associated factor 1 multiple interactions ISO [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of TRAF1 mRNA CTD PMID:22975265 NCBI chr 3:14,003,340...14,022,955
Ensembl chr 3:14,003,340...14,022,672
JBrowse link
G Tymp thymidine phosphorylase increases response to substance ISO TYMP protein results in increased susceptibility to Pemetrexed CTD PMID:17575230 NCBI chr 7:130,342,481...130,347,845
Ensembl chr 7:130,342,483...130,347,587
JBrowse link
G Tyms thymidylate synthetase decreases activity
multiple interactions
affects response to substance
ISO Pemetrexed results in decreased activity of TYMS protein
TYMS protein inhibits the reaction [Pemetrexed results in increased expression of FAS protein]
TYMS affects the susceptibility to Pemetrexed; TYMS protein affects the susceptibility to Pemetrexed
CTD PMID:15161716, PMID:17339891, PMID:21742432 NCBI chr 9:121,918,875...121,931,564
Ensembl chr 9:121,918,947...121,931,564
JBrowse link
pevonedistat term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bbc3 Bcl-2 binding component 3 affects expression ISO pevonedistat affects the expression of BBC3 mRNA CTD PMID:24634471 NCBI chr 1:78,261,491...78,267,802 JBrowse link
G Bcl2 BCL2, apoptosis regulator affects expression ISO pevonedistat affects the expression of BCL2 mRNA CTD PMID:24634471 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bcl2l1 Bcl2-like 1 affects expression ISO pevonedistat affects the expression of BCL2L1 mRNA CTD PMID:24634471 NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
JBrowse link
G Bcl2l11 BCL2 like 11 affects expression ISO pevonedistat affects the expression of BCL2L11 mRNA; pevonedistat affects the expression of BCL2L11 protein CTD PMID:24634471 NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
JBrowse link
G Casp3 caspase 3 multiple interactions ISO pevonedistat results in increased cleavage of and results in increased activity of CASP3 protein; Tretinoin promotes the reaction [pevonedistat results in increased cleavage of and results in increased activity of CASP3 protein] CTD PMID:22110742 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Ccl17 C-C motif chemokine ligand 17 affects expression ISO pevonedistat affects the expression of CCL17 mRNA CTD PMID:24634471 NCBI chr19:10,619,220...10,620,671
Ensembl chr19:10,619,220...10,620,671
JBrowse link
G Ccl22 C-C motif chemokine ligand 22 affects expression ISO pevonedistat affects the expression of CCL22 mRNA CTD PMID:24634471 NCBI chr19:10,674,189...10,681,145
Ensembl chr19:10,674,189...10,681,145
JBrowse link
G Ccl5 C-C motif chemokine ligand 5 affects expression ISO pevonedistat affects the expression of CCL5 mRNA CTD PMID:24634471 NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
JBrowse link
G Ccnd1 cyclin D1 affects expression ISO pevonedistat affects the expression of CCND1 mRNA CTD PMID:24634471 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Ccnd2 cyclin D2 affects expression ISO pevonedistat affects the expression of CCND2 mRNA CTD PMID:24634471 NCBI chr 4:159,674,885...159,697,207
Ensembl chr 4:159,674,885...159,697,207
JBrowse link
G Cd40 CD40 molecule affects expression ISO pevonedistat affects the expression of CD40 mRNA CTD PMID:24634471 NCBI chr 3:161,519,789...161,534,943
Ensembl chr 3:161,519,743...161,534,704
JBrowse link
G Cd74 CD74 molecule affects expression ISO pevonedistat affects the expression of CD74 mRNA CTD PMID:24634471 NCBI chr18:56,071,420...56,080,851
Ensembl chr18:56,071,478...56,080,849
JBrowse link
G Cdt1 chromatin licensing and DNA replication factor 1 increases abundance ISO pevonedistat results in increased abundance of CDT1 protein CTD PMID:22110742 NCBI chr19:55,381,565...55,386,511
Ensembl chr19:55,381,565...55,386,511
JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator affects expression ISO pevonedistat affects the expression of CFLAR mRNA CTD PMID:24634471 NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
JBrowse link
G Ctnnb1 catenin beta 1 increases abundance ISO pevonedistat results in increased abundance of CTNNB1 protein CTD PMID:22110742 NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
JBrowse link
G Cul1 cullin 1 decreases metabolic processing ISO pevonedistat results in decreased metabolism of CUL1 protein CTD PMID:22110742 NCBI chr 4:77,211,814...77,283,369
Ensembl chr 4:77,211,692...77,280,250
JBrowse link
G Cxcl9 C-X-C motif chemokine ligand 9 affects expression ISO pevonedistat affects the expression of CXCL9 mRNA CTD PMID:24634471 NCBI chr14:17,228,832...17,233,743
Ensembl chr14:17,228,856...17,234,712
JBrowse link
G Cxcr3 C-X-C motif chemokine receptor 3 affects expression ISO pevonedistat affects the expression of CXCR3 mRNA CTD PMID:24634471 NCBI chr  X:71,614,346...71,616,997
Ensembl chr  X:71,614,346...71,616,997
JBrowse link
G Cxcr5 C-X-C motif chemokine receptor 5 affects expression ISO pevonedistat affects the expression of CXCR5 mRNA CTD PMID:24634471 NCBI chr 8:48,835,688...48,852,032
Ensembl chr 8:48,836,957...48,850,671
JBrowse link
G Gadd45b growth arrest and DNA-damage-inducible, beta affects expression ISO pevonedistat affects the expression of GADD45B mRNA CTD PMID:24634471 NCBI chr 7:11,646,283...11,648,338
Ensembl chr 7:11,646,269...11,648,322
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit increases abundance
multiple interactions
ISO pevonedistat results in increased abundance of JUN protein
Tretinoin promotes the reaction [pevonedistat results in increased abundance of JUN protein]
CTD PMID:22110742 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
JBrowse link
G Maf1 MAF1 homolog, negative regulator of RNA polymerase III increases expression ISO pevonedistat results in increased expression of MAF1 protein CTD PMID:31645432 NCBI chr 7:117,417,643...117,420,722
Ensembl chr 7:117,417,687...117,420,719
JBrowse link
G Mir155hg Mir155 host gene affects expression ISO pevonedistat affects the expression of MIR155HG mRNA CTD PMID:24634471 NCBI chr11:24,175,417...24,177,646 JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor increases expression ISO pevonedistat results in increased expression of MYC protein CTD PMID:25897075 NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 affects activity ISO pevonedistat affects the activity of NFKB1 protein CTD PMID:24634471 NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
JBrowse link
G Nfkbia NFKB inhibitor alpha increases phosphorylation ISO pevonedistat results in increased phosphorylation of NFKBIA protein CTD PMID:22110742, PMID:24634471 NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 increases cleavage
multiple interactions
ISO pevonedistat results in increased cleavage of PARP1 protein
pevonedistat results in increased cleavage of and results in increased activity of PARP1 protein; Tretinoin promotes the reaction [pevonedistat results in increased cleavage of and results in increased activity of PARP1 protein]
CTD PMID:22110742, PMID:24634471 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Pmaip1 phorbol-12-myristate-13-acetate-induced protein 1 increases abundance
affects expression
multiple interactions
ISO pevonedistat results in increased abundance of PMAIP1 protein
pevonedistat affects the expression of PMAIP1 mRNA
Tretinoin promotes the reaction [pevonedistat results in increased abundance of PMAIP1 protein]
CTD PMID:22110742, PMID:24634471 NCBI chr18:62,159,128...62,179,635
Ensembl chr18:62,174,670...62,181,102
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit affects activity ISO pevonedistat affects the activity of RELA protein CTD PMID:24634471 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G Rictor RPTOR independent companion of MTOR, complex 2 increases expression ISO pevonedistat results in increased expression of RICTOR protein CTD PMID:25897075 NCBI chr 2:56,013,898...56,105,818
Ensembl chr 2:56,052,643...56,101,803
JBrowse link
G Rptor regulatory associated protein of MTOR, complex 1 increases expression ISO pevonedistat results in increased expression of RPTOR protein CTD PMID:25897075 NCBI chr10:108,750,620...109,058,691
Ensembl chr10:108,750,620...109,058,691
JBrowse link
G Sall4 spalt-like transcription factor 4 multiple interactions ISO pevonedistat inhibits the reaction [Thalidomide results in increased degradation of and results in decreased expression of SALL4 protein] CTD PMID:30067223 NCBI chr 3:165,520,155...165,538,176
Ensembl chr 3:165,520,392...165,537,940
JBrowse link
G Stat5a signal transducer and activator of transcription 5A affects expression ISO pevonedistat affects the expression of STAT5A mRNA CTD PMID:24634471 NCBI chr10:88,764,732...88,789,060
Ensembl chr10:88,764,732...88,789,057
JBrowse link
G Uba3 ubiquitin-like modifier activating enzyme 3 decreases activity ISO pevonedistat results in decreased activity of UBA3 protein CTD PMID:22110742 NCBI chr 4:129,548,411...129,569,550
Ensembl chr 4:129,548,416...129,569,470
JBrowse link
G Wee1 WEE1 G2 checkpoint kinase increases abundance ISO pevonedistat results in increased abundance of WEE1 protein CTD PMID:22110742 NCBI chr 1:174,765,228...174,790,882
Ensembl chr 1:174,767,960...174,786,361
JBrowse link
PF-956980 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ccl2 C-C motif chemokine ligand 2 multiple interactions ISO PF 956980 inhibits the reaction [OSM protein results in increased expression of CCL2 mRNA] CTD PMID:23968543 NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
JBrowse link
G Jak3 Janus kinase 3 multiple interactions ISO PF 956980 inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK3 protein] CTD PMID:23968543 NCBI chr16:20,107,471...20,120,678
Ensembl chr16:20,109,200...20,120,668
JBrowse link
G Osm oncostatin M multiple interactions ISO PF 956980 inhibits the reaction [OSM protein results in increased expression of CCL2 mRNA]; PF 956980 inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK3 protein]; PF 956980 inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of STAT1 protein] CTD PMID:23968543 NCBI chr14:84,457,487...84,469,426
Ensembl chr14:84,465,515...84,470,409
JBrowse link
G Stat1 signal transducer and activator of transcription 1 multiple interactions ISO PF 956980 inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of STAT1 protein] CTD PMID:23968543 NCBI chr 9:54,287,540...54,327,958
Ensembl chr 9:54,287,541...54,484,533
JBrowse link
tofacitinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ahr aryl hydrocarbon receptor multiple interactions ISO tofacitinib inhibits the reaction [[IL6 protein co-treated with TGFB1 protein] results in increased expression of AHR mRNA] CTD PMID:21383241 NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO tofacitinib inhibits the reaction [IL2 protein results in increased phosphorylation of AKT1 protein] CTD PMID:21383241 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Ampd2 adenosine monophosphate deaminase 2 multiple interactions
decreases expression
ISO [tofacitinib results in decreased expression of AMPD2 protein] which affects the abundance of Adenosine CTD PMID:25496463 NCBI chr 2:210,861,624...210,874,348
Ensembl chr 2:210,861,625...210,874,304
JBrowse link
G Bst2 bone marrow stromal cell antigen 2 decreases expression ISO tofacitinib results in decreased expression of BST2 mRNA CTD PMID:25487280 NCBI chr16:19,938,781...19,942,353
Ensembl chr16:19,938,784...19,942,353
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 decreases expression
multiple interactions
ISO tofacitinib results in decreased expression of CCL2 mRNA
Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; tofacitinib inhibits the reaction [OSM protein results in increased expression of CCL2 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL2 protein]
CTD PMID:22121136, PMID:23968543, PMID:25398374 NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
JBrowse link
G Ccl5 C-C motif chemokine ligand 5 multiple interactions ISO Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL5 protein]]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL5 protein] CTD PMID:22121136 NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
JBrowse link
G Ccnd1 cyclin D1 increases expression ISO tofacitinib results in increased expression of CCND1 mRNA CTD PMID:26300391 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Ctsk cathepsin K decreases expression ISO tofacitinib results in decreased expression of CTSK protein CTD PMID:21937456 NCBI chr 2:196,655,469...196,666,447
Ensembl chr 2:196,655,469...196,666,446
JBrowse link
G Cxcl10 C-X-C motif chemokine ligand 10 decreases expression
multiple interactions
decreases secretion
ISO
EXP
tofacitinib results in decreased expression of CXCL10 mRNA
Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]
tofacitinib inhibits the reaction [IFNG protein results in increased expression of CXCL10 mRNA]
tofacitinib results in decreased secretion of CXCL10 protein
CTD PMID:22121136, PMID:22899318, PMID:22941906, PMID:24213371, PMID:25398374, PMID:25487280 NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
JBrowse link
G Cxcl11 C-X-C motif chemokine ligand 11 decreases expression
multiple interactions
ISO tofacitinib results in decreased expression of CXCL11 mRNA
tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL11 mRNA]
CTD PMID:22941906 NCBI chr14:17,195,395...17,198,170
Ensembl chr14:17,195,014...17,198,291
JBrowse link
G Cxcl13 C-X-C motif chemokine ligand 13 decreases expression ISO tofacitinib results in decreased expression of CXCL13 mRNA CTD PMID:25398374 NCBI chr14:15,253,146...15,258,221
Ensembl chr14:15,253,125...15,258,207
JBrowse link
G Cxcl9 C-X-C motif chemokine ligand 9 multiple interactions
decreases expression
ISO tofacitinib inhibits the reaction [IFNG protein results in increased expression of CXCL9 mRNA]
tofacitinib results in decreased expression of CXCL9 mRNA
CTD PMID:22941906, PMID:24213371 NCBI chr14:17,228,832...17,233,743
Ensembl chr14:17,228,856...17,234,712
JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 increases metabolic processing ISO CYP1A2 protein results in increased metabolism of tofacitinib CTD PMID:31414593 NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
JBrowse link
G Cyp2c6v1 cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 increases metabolic processing ISO CYP2C19 protein results in increased metabolism of tofacitinib CTD PMID:31414593 NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
JBrowse link
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 increases metabolic processing ISO CYP2D6 protein results in increased metabolism of tofacitinib CTD PMID:31414593 NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
JBrowse link
G Gli1 GLI family zinc finger 1 increases expression ISO tofacitinib results in increased expression of GLI1 mRNA CTD PMID:25487280 NCBI chr 7:70,620,794...70,633,171
Ensembl chr 7:70,620,766...70,630,338
JBrowse link
G Ifi27 interferon, alpha-inducible protein 27 decreases expression ISO tofacitinib results in decreased expression of IFI27 mRNA CTD PMID:25487280 NCBI chr 6:127,327,959...127,334,430
Ensembl chr 6:127,327,959...127,334,428
JBrowse link
G Ifi35 interferon-induced protein 35 decreases expression ISO tofacitinib results in decreased expression of IFI35 mRNA CTD PMID:25487280 NCBI chr10:89,358,376...89,366,628
Ensembl chr10:89,358,376...89,366,626
JBrowse link
G Ifi44 interferon-induced protein 44 decreases expression ISO tofacitinib results in decreased expression of IFI44 mRNA CTD PMID:25487280 NCBI chr 2:256,897,765...256,915,591
Ensembl chr 2:256,897,772...256,915,569
JBrowse link
G Ifit3 interferon-induced protein with tetratricopeptide repeats 3 decreases expression ISO tofacitinib results in decreased expression of IFIT3 mRNA CTD PMID:25487280 NCBI chr 1:252,906,234...252,911,377
Ensembl chr 1:252,906,234...252,911,382
JBrowse link
G Ifng interferon gamma multiple interactions ISO tofacitinib inhibits the reaction [IFNG protein results in increased expression of CXCL10 mRNA]; tofacitinib inhibits the reaction [IFNG protein results in increased expression of CXCL9 mRNA]; tofacitinib inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IFNG protein]
tofacitinib inhibits the reaction [IFNG protein affects the localization of and results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [IFNG protein affects the localization of and results in increased phosphorylation of STAT2 protein]
CTD PMID:21383241, PMID:22941906, PMID:24213371 NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
JBrowse link
G Il10 interleukin 10 multiple interactions ISO tofacitinib inhibits the reaction [IL6 protein results in increased expression of IL10 mRNA]; tofacitinib inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL10 protein] CTD PMID:21383241, PMID:24285838 NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
JBrowse link
G Il15 interleukin 15 multiple interactions ISO tofacitinib inhibits the reaction [IL15 protein results in increased phosphorylation of STAT5A protein]; tofacitinib inhibits the reaction [IL15 protein results in increased phosphorylation of STAT5B protein] CTD PMID:21155605 NCBI chr19:23,542,606...23,624,366
Ensembl chr19:23,542,889...23,554,594
JBrowse link
G Il17a interleukin 17A multiple interactions ISO tofacitinib inhibits the reaction [enterotoxin A, Staphylococcal results in increased expression of and results in increased secretion of IL17A protein] CTD PMID:26738536 NCBI chr 9:26,841,299...26,844,786
Ensembl chr 9:26,841,299...26,844,786
JBrowse link
G Il1b interleukin 1 beta multiple interactions
decreases expression
ISO
EXP
tofacitinib inhibits the reaction [IL1B protein results in increased expression of IL6 mRNA]; tofacitinib inhibits the reaction [IL1B protein results in increased expression of IL6 protein]; tofacitinib inhibits the reaction [IL1B protein results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL1B protein]
tofacitinib inhibits the reaction [TNF protein affects the expression of IL1B mRNA]
tofacitinib results in decreased expression of IL1B mRNA
CTD PMID:21383241, PMID:21937456, PMID:22899318, PMID:22941906 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Il2 interleukin 2 multiple interactions ISO tofacitinib inhibits the reaction [IL2 protein results in increased phosphorylation of AKT1 protein]; tofacitinib inhibits the reaction [IL2 protein results in increased phosphorylation of STAT5A protein]; tofacitinib inhibits the reaction [IL2 protein results in increased phosphorylation of STAT5B protein] CTD PMID:21155605, PMID:21383241 NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
JBrowse link
G Il21 interleukin 21 multiple interactions ISO tofacitinib inhibits the reaction [IL21 protein results in increased phosphorylation of STAT3 protein]
tofacitinib inhibits the reaction [IL21 protein results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [IL21 protein results in increased phosphorylation of STAT3 protein]
CTD PMID:21383241 NCBI chr 2:123,965,021...123,972,356
Ensembl chr 2:123,965,021...123,972,356
JBrowse link
G Il23a interleukin 23 subunit alpha multiple interactions ISO tofacitinib inhibits the reaction [[IL6 protein co-treated with IL23A protein] results in increased expression of IL23R mRNA]; tofacitinib inhibits the reaction [[IL6 protein co-treated with IL23A protein] results in increased expression of RORC mRNA]; tofacitinib inhibits the reaction [IL23A protein results in increased phosphorylation of STAT3 protein] CTD PMID:21383241, PMID:21937456 NCBI chr 7:2,710,609...2,712,723
Ensembl chr 7:2,710,609...2,712,723
JBrowse link
G Il23r interleukin 23 receptor multiple interactions ISO tofacitinib inhibits the reaction [[IL6 protein co-treated with IL23A protein] results in increased expression of IL23R mRNA] CTD PMID:21383241 NCBI chr 4:98,203,788...98,306,729
Ensembl chr 4:98,203,958...98,305,173
JBrowse link
G Il4 interleukin 4 multiple interactions ISO tofacitinib inhibits the reaction [IL4 protein results in increased phosphorylation of STAT6 protein] CTD PMID:21383241 NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
JBrowse link
G Il6 interleukin 6 decreases expression
multiple interactions
ISO
EXP
tofacitinib results in decreased expression of IL6 mRNA
tofacitinib inhibits the reaction [[IL6 protein co-treated with IL6R protein] results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [IL6 protein results in increased expression of SAA1 mRNA]; tofacitinib inhibits the reaction [IL6 protein results in increased expression of SAA2 mRNA]; tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of JAK2 protein]; tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [Mustard Gas results in increased secretion of IL6 protein]; tofacitinib inhibits the reaction [OSM protein results in increased expression of and results in increased secretion of IL6 protein]; tofacitinib inhibits the reaction [OSM protein results in increased expression of IL6 mRNA]
tofacitinib results in decreased expression of and results in decreased secretion of IL6 protein
tofacitinib inhibits the reaction [[IL6 protein co-treated with IL23A protein] results in increased expression of IL23R mRNA]; tofacitinib inhibits the reaction [[IL6 protein co-treated with IL23A protein] results in increased expression of RORC mRNA]; tofacitinib inhibits the reaction [[IL6 protein co-treated with TGFB1 protein] results in increased expression of AHR mRNA]; tofacitinib inhibits the reaction [[IL6 protein co-treated with TGFB1 protein] results in increased expression of RORC mRNA]; tofacitinib inhibits the reaction [IL1B protein results in increased expression of IL6 mRNA]; tofacitinib inhibits the reaction [IL1B protein results in increased expression of IL6 protein]; tofacitinib inhibits the reaction [IL6 protein results in increased expression of IL10 mRNA]; tofacitinib inhibits the reaction [IL6 protein results in increased expression of IL6 mRNA]; tofacitinib inhibits the reaction [IL6 protein results in increased expression of TNFSF11 mRNA]; tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL6 protein]; tofacitinib inhibits the reaction [OSM protein results in increased expression of IL6 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of IL6 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of IL6 protein]; tofacitinib promotes the reaction [IL6 protein results in increased expression of MMP9 mRNA]
CTD PMID:21383241, PMID:21548952, PMID:21844139, PMID:21937456, PMID:22121136, PMID:22899318, PMID:22941906, PMID:24285838, PMID:31048000 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Il6r interleukin 6 receptor multiple interactions ISO tofacitinib inhibits the reaction [[IL6 protein co-treated with IL6R protein] results in increased phosphorylation of STAT3 protein] CTD PMID:21548952 NCBI chr 2:189,196,180...189,255,987
Ensembl chr 2:189,205,701...189,254,628
JBrowse link
G Irf7 interferon regulatory factor 7 decreases expression ISO tofacitinib results in decreased expression of IRF7 mRNA CTD PMID:22941906, PMID:25487280 NCBI chr 1:214,249,388...214,252,909
Ensembl chr 1:214,248,837...214,252,456
JBrowse link
G Irf9 interferon regulatory factor 9 decreases expression ISO tofacitinib results in decreased expression of IRF9 mRNA CTD PMID:25487280 NCBI chr15:34,282,936...34,288,981
Ensembl chr15:34,282,936...34,288,138
JBrowse link
G Isg15 ISG15 ubiquitin-like modifier decreases expression ISO tofacitinib results in decreased expression of ISG15 mRNA CTD PMID:25487280 NCBI chr 5:173,624,862...173,629,124
Ensembl chr 5:173,624,310...173,626,248
JBrowse link
G Jak1 Janus kinase 1 decreases activity
multiple interactions
ISO tofacitinib results in decreased activity of JAK1 protein
tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK1 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of JAK1 protein]
CTD PMID:21548952, PMID:23968543, PMID:24883332 NCBI chr 5:119,982,503...120,091,452
Ensembl chr 5:119,982,943...120,083,904
JBrowse link
G Jak2 Janus kinase 2 affects response to substance
multiple interactions
decreases activity
ISO JAK2 gene mutant form affects the susceptibility to tofacitinib
tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of JAK2 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK2 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of JAK2 protein]
tofacitinib results in decreased activity of JAK2 protein
CTD PMID:21548952, PMID:21844139, PMID:23968543, PMID:26300391 NCBI chr 1:247,398,667...247,457,521
Ensembl chr 1:247,398,598...247,458,509
JBrowse link
G Jak3 Janus kinase 3 decreases activity
multiple interactions
ISO tofacitinib results in decreased activity of JAK3 protein
tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK3 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of JAK3 protein]
CTD PMID:21548952, PMID:23689514, PMID:23968543, PMID:24883332, PMID:26300391, PMID:26738536 NCBI chr16:20,107,471...20,120,678
Ensembl chr16:20,109,200...20,120,668
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO tofacitinib promotes the reaction [TNF protein affects the localization of JUN protein] CTD PMID:22941906 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
JBrowse link
G Klhl31 kelch-like family member 31 increases expression ISO tofacitinib results in increased expression of KLHL31 mRNA CTD PMID:25487280 NCBI chr 8:84,945,444...84,968,811
Ensembl chr 8:84,945,444...84,968,811
JBrowse link
G Krt16 keratin 16 decreases expression ISO tofacitinib results in decreased expression of KRT16 mRNA CTD PMID:27059729 NCBI chr10:88,149,210...88,152,167
Ensembl chr10:88,149,345...88,152,064
JBrowse link
G Lhcgr luteinizing hormone/choriogonadotropin receptor multiple interactions EXP tofacitinib inhibits the reaction [PRL protein results in increased expression of LHCGR mRNA] CTD PMID:27708194 NCBI chr 6:12,493,182...12,554,482
Ensembl chr 6:12,493,943...12,554,439
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of MAPK1 protein] CTD PMID:21548952 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of MAPK3 protein] CTD PMID:21548952 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions ISO tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of MAPK8 protein] CTD PMID:21548952 NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions ISO tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of MAPK9 protein] CTD PMID:21548952 NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
JBrowse link
G Mmp1 matrix metallopeptidase 1 decreases expression ISO tofacitinib results in decreased expression of MMP1 mRNA CTD PMID:25398374 NCBI chr 8:5,703,206...5,723,593
Ensembl chr 8:5,703,206...5,723,591
JBrowse link
G Mmp3 matrix metallopeptidase 3 decreases expression ISO tofacitinib results in decreased expression of MMP3 mRNA CTD PMID:25398374 NCBI chr 8:5,676,608...5,698,579
Ensembl chr 8:5,676,665...5,698,579
JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions ISO tofacitinib promotes the reaction [IL6 protein results in increased expression of MMP9 mRNA] CTD PMID:24285838 NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
JBrowse link
G Mt-co1 mitochondrially encoded cytochrome c oxidase I increases expression ISO tofacitinib results in increased expression of COX1 protein CTD PMID:25487280 NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867
JBrowse link
G Mx2 MX dynamin like GTPase 2 decreases expression ISO tofacitinib results in decreased expression of MX1 mRNA CTD PMID:25487280 NCBI chr11:38,035,306...38,066,185
Ensembl chr11:38,035,450...38,059,950
JBrowse link
G Nfatc1 nuclear factor of activated T-cells 1 multiple interactions ISO tofacitinib promotes the reaction [TNF protein affects the localization of NFATC1 protein] CTD PMID:22941906 NCBI chr18:77,203,517...77,322,690
Ensembl chr18:77,203,525...77,322,690
JBrowse link
G Nfkb2 nuclear factor kappa B subunit 2 multiple interactions ISO tofacitinib inhibits the reaction [TNF protein affects the localization of NFKB2 protein] CTD PMID:22941906 NCBI chr 1:266,050,634...266,059,277
Ensembl chr 1:266,053,002...266,059,256
JBrowse link
G Oas1a 2'-5' oligoadenylate synthetase 1A decreases expression ISO tofacitinib results in decreased expression of OAS1 mRNA CTD PMID:25487280 NCBI chr12:41,200,680...41,211,393
Ensembl chr12:41,200,718...41,211,909
JBrowse link
G Oas2 2'-5' oligoadenylate synthetase 2 decreases expression ISO tofacitinib results in decreased expression of OAS2 mRNA CTD PMID:25487280 NCBI chr12:41,341,417...41,363,124
Ensembl chr12:41,340,815...41,363,161
JBrowse link
G Osm oncostatin M multiple interactions ISO tofacitinib inhibits the reaction [OSM protein results in increased expression of IL6 mRNA]; tofacitinib inhibits the reaction [OSM protein results in increased expression of TNFSF11 mRNA]
tofacitinib inhibits the reaction [OSM protein results in increased expression of and results in increased secretion of IL6 protein]; tofacitinib inhibits the reaction [OSM protein results in increased expression of CCL2 mRNA]; tofacitinib inhibits the reaction [OSM protein results in increased expression of IL6 mRNA]; tofacitinib inhibits the reaction [OSM protein results in increased expression of S100A7 protein]; tofacitinib inhibits the reaction [OSM protein results in increased expression of SAA1 mRNA]; tofacitinib inhibits the reaction [OSM protein results in increased expression of SAA2 mRNA]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK1 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK2 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK3 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of STAT1 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of STAT3 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of JAK1 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of JAK2 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of JAK3 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of MAPK1 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of MAPK3 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of MAPK8 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of MAPK9 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of STAT3 protein]
CTD PMID:21548952, PMID:21937456, PMID:23968543, PMID:25252914 NCBI chr14:84,457,487...84,469,426
Ensembl chr14:84,465,515...84,470,409
JBrowse link
G Prdm16 PR/SET domain 16 increases expression ISO tofacitinib results in increased expression of PRDM16 protein CTD PMID:25487280 NCBI chr 5:171,662,277...171,711,561
Ensembl chr 5:171,662,277...171,710,316
JBrowse link
G Prl prolactin multiple interactions EXP tofacitinib inhibits the reaction [PRL protein results in increased expression of LHCGR mRNA]; tofacitinib inhibits the reaction [PRL protein results in increased phosphorylation of STAT5A protein]; tofacitinib inhibits the reaction [PRL protein results in increased phosphorylation of STAT5B protein] CTD PMID:27708194 NCBI chr17:39,814,236...39,824,299
Ensembl chr17:39,814,244...39,824,299
JBrowse link
G Relb RELB proto-oncogene, NF-kB subunit multiple interactions ISO tofacitinib inhibits the reaction [TNF protein affects the localization of RELB protein] CTD PMID:22941906 NCBI chr 1:80,517,081...80,545,019
Ensembl chr 1:80,517,411...80,544,825
JBrowse link
G Rorc RAR-related orphan receptor C multiple interactions ISO tofacitinib inhibits the reaction [[IL6 protein co-treated with IL23A protein] results in increased expression of RORC mRNA]; tofacitinib inhibits the reaction [[IL6 protein co-treated with TGFB1 protein] results in increased expression of RORC mRNA] CTD PMID:21383241 NCBI chr 2:195,612,471...195,636,797
Ensembl chr 2:195,617,021...195,637,630
JBrowse link
G Rsad2 radical S-adenosyl methionine domain containing 2 decreases expression ISO tofacitinib results in decreased expression of RSAD2 mRNA CTD PMID:25487280 NCBI chr 6:45,655,947...45,669,083
Ensembl chr 6:45,655,954...45,669,148
JBrowse link
G Sdha succinate dehydrogenase complex flavoprotein subunit A increases expression ISO tofacitinib results in increased expression of SDHA protein CTD PMID:25487280 NCBI chr 1:31,545,631...31,570,601
Ensembl chr 1:31,545,631...31,570,601
JBrowse link
G Sele selectin E decreases expression EXP tofacitinib results in decreased expression of SELE mRNA CTD PMID:22899318 NCBI chr13:82,355,234...82,365,323
Ensembl chr13:82,355,471...82,365,341
JBrowse link
G Selp selectin P decreases expression EXP tofacitinib results in decreased expression of SELP mRNA CTD PMID:22899318 NCBI chr13:82,428,914...82,464,629
Ensembl chr13:82,429,063...82,464,628
JBrowse link
G Sfrp5 secreted frizzled-related protein 5 increases expression ISO tofacitinib results in increased expression of SFRP5 mRNA CTD PMID:25487280 NCBI chr 1:261,442,108...261,446,570
Ensembl chr 1:261,442,108...261,446,570
JBrowse link
G Shh sonic hedgehog signaling molecule increases expression ISO tofacitinib results in increased expression of SHH mRNA CTD PMID:25487280 NCBI chr 4:718,538...727,691
Ensembl chr 4:718,538...727,691
JBrowse link
G Socs3 suppressor of cytokine signaling 3 decreases expression ISO tofacitinib results in decreased expression of SOCS3 mRNA CTD PMID:25487280 NCBI chr10:106,973,863...106,976,969
Ensembl chr10:106,975,178...106,976,040
JBrowse link
G Stat1 signal transducer and activator of transcription 1 decreases expression
multiple interactions
decreases phosphorylation
ISO tofacitinib results in decreased expression of STAT1 mRNA; tofacitinib results in decreased expression of STAT1 protein modified form
tofacitinib inhibits the reaction [IFNA1 protein affects the localization of and results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [IFNG protein affects the localization of and results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of STAT1 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [TNF protein affects the localization of and results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [TNF protein results in increased phosphorylation of STAT1 protein]
tofacitinib inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [IL21 protein results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of STAT1 protein]
tofacitinib results in decreased phosphorylation of STAT1 protein
CTD PMID:21383241, PMID:21548952, PMID:22121136, PMID:22941906, PMID:23968543, PMID:25398374, PMID:25487280, PMID:27059729, PMID:28365849 NCBI chr 9:54,287,540...54,327,958
Ensembl chr 9:54,287,541...54,484,533
JBrowse link
G Stat2 signal transducer and activator of transcription 2 multiple interactions ISO tofacitinib inhibits the reaction [IFNA1 protein affects the localization of and results in increased phosphorylation of STAT2 protein]; tofacitinib inhibits the reaction [IFNG protein affects the localization of and results in increased phosphorylation of STAT2 protein] CTD PMID:22941906 NCBI chr 7:2,691,064...2,707,530
Ensembl chr 7:2,691,369...2,707,741
JBrowse link
G Stat3 signal transducer and activator of transcription 3 decreases activity
multiple interactions
decreases expression
decreases phosphorylation
ISO tofacitinib results in decreased activity of STAT3 protein
tofacitinib inhibits the reaction [[IL6 protein co-treated with IL6R protein] results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [IL21 protein results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of STAT3 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of STAT3 protein]
tofacitinib inhibits the reaction [IL1B protein results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [IL21 protein results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [IL23A protein results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein]
tofacitinib results in decreased expression of STAT3 protein modified form
tofacitinib results in decreased phosphorylation of STAT3 protein
CTD PMID:21383241, PMID:21548952, PMID:21844139, PMID:21937456, PMID:22121136, PMID:22348037, PMID:23968543, PMID:24285838, PMID:25252914, PMID:25398374, PMID:25487280, PMID:26244872, PMID:27059729 NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
JBrowse link
G Stat5a signal transducer and activator of transcription 5A decreases phosphorylation
multiple interactions
ISO
EXP
tofacitinib results in decreased phosphorylation of STAT5A protein
tofacitinib inhibits the reaction [PRL protein results in increased phosphorylation of STAT5A protein]
tofacitinib inhibits the reaction [IL2 protein results in increased phosphorylation of STAT5A protein]
tofacitinib inhibits the reaction [IL15 protein results in increased phosphorylation of STAT5A protein]
CTD PMID:21155605, PMID:22705984, PMID:26244872, PMID:27708194 NCBI chr10:88,764,732...88,789,060
Ensembl chr10:88,764,732...88,789,057
JBrowse link
G Stat5b signal transducer and activator of transcription 5B decreases phosphorylation
multiple interactions
ISO
EXP
tofacitinib results in decreased phosphorylation of STAT5B protein; tofacitinib results in decreased phosphorylation of STAT5B protein mutant form
tofacitinib inhibits the reaction [IL2 protein results in increased phosphorylation of STAT5B protein]
tofacitinib inhibits the reaction [PRL protein results in increased phosphorylation of STAT5B protein]
tofacitinib inhibits the reaction [IL15 protein results in increased phosphorylation of STAT5B protein]
CTD PMID:21155605, PMID:22705984, PMID:26244872, PMID:27708194, PMID:29200404 NCBI chr10:88,686,207...88,712,313
Ensembl chr10:88,686,207...88,754,829
JBrowse link
G Stat6 signal transducer and activator of transcription 6 multiple interactions ISO tofacitinib inhibits the reaction [IL4 protein results in increased phosphorylation of STAT6 protein] CTD PMID:21383241 NCBI chr 7:70,946,228...70,963,542
Ensembl chr 7:70,946,228...70,964,484
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO tofacitinib inhibits the reaction [[IL6 protein co-treated with TGFB1 protein] results in increased expression of AHR mRNA]; tofacitinib inhibits the reaction [[IL6 protein co-treated with TGFB1 protein] results in increased expression of RORC mRNA] CTD PMID:21383241 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL5 protein]]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]]; tofacitinib inhibits the reaction [TNF protein affects the expression of IL1B mRNA]; tofacitinib inhibits the reaction [TNF protein affects the localization of and results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [TNF protein affects the localization of NFKB2 protein]; tofacitinib inhibits the reaction [TNF protein affects the localization of RELB protein]; tofacitinib inhibits the reaction [TNF protein results in decreased expression of UCP1 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL2 protein]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL5 protein]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL11 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of IFIT1 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased phosphorylation of STAT1 protein]; tofacitinib promotes the reaction [TNF protein affects the localization of JUN protein]; tofacitinib promotes the reaction [TNF protein affects the localization of NFATC1 protein]
tofacitinib inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of TNF protein]; tofacitinib inhibits the reaction [TNF protein results in increased expression of IL6 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of IL6 protein]; tofacitinib inhibits the reaction [TNF protein results in increased expression of TNFSF11 mRNA]
CTD PMID:21383241, PMID:21937456, PMID:22121136, PMID:22941906, PMID:25487280 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tnfsf10 TNF superfamily member 10 decreases expression ISO tofacitinib results in decreased expression of TNFSF10 mRNA CTD PMID:25487280 NCBI chr 2:113,008,008...113,026,899
Ensembl chr 2:113,007,549...113,026,899
JBrowse link
G Tnfsf11 TNF superfamily member 11 multiple interactions
decreases expression
ISO
EXP
tofacitinib results in decreased expression of and results in decreased secretion of TNFSF11 protein
tofacitinib results in decreased expression of TNFSF11 protein
tofacitinib results in decreased expression of TNFSF11 mRNA
tofacitinib inhibits the reaction [IL6 protein results in increased expression of TNFSF11 mRNA]; tofacitinib inhibits the reaction [OSM protein results in increased expression of TNFSF11 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of TNFSF11 mRNA]
CTD PMID:21937456, PMID:22899318 NCBI chr15:60,482,527...60,512,704
Ensembl chr15:60,482,527...60,512,704
JBrowse link
G Ucp1 uncoupling protein 1 increases expression
multiple interactions
ISO tofacitinib results in increased expression of UCP1 mRNA; tofacitinib results in increased expression of UCP1 protein
cyclopamine inhibits the reaction [tofacitinib results in increased expression of UCP1 mRNA]; tofacitinib inhibits the reaction [TNF protein results in decreased expression of UCP1 mRNA]
CTD PMID:25487280 NCBI chr19:24,456,976...24,464,808
Ensembl chr19:24,456,976...24,464,807
JBrowse link
G Usp18 ubiquitin specific peptidase 18 decreases expression ISO tofacitinib results in decreased expression of USP18 mRNA CTD PMID:25487280 NCBI chr 4:153,812,312...153,834,374
Ensembl chr 4:153,805,993...153,834,430
JBrowse link
G Vegfa vascular endothelial growth factor A increases expression ISO tofacitinib results in increased expression of VEGFA mRNA CTD PMID:26300391 NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19816
    chemical entity 19816
      atom 19814
        nonmetal atom 19690
          nitrogen atom 18565
            nitrogen molecular entity 18565
              organonitrogen compound 18338
                organonitrogen heterocyclic compound 17485
                  pyrrolopyrimidine 166
                    ((2S,3aS,4R,6S)-4-(hydroxymethyl)-6-(4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-7-yl)tetrahydrofuro[3,4-d][1,3]dioxol-2-yl)methylphosphonic acid 0
                    (1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol 5-phosphate 0
                    (2R)-1-[(5,6-diphenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]propan-2-ol 0
                    (2R)-3-\{[(4Z)-5,6-diphenyl-6,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-ylidene]amino\}propane-1,2-diol 0
                    (2S)-1-[(8aR)-hexahydropyrrolo[1,2-a]pyrimidin-1(2H)-yl]-4-methylpentan-2-amine 0
                    (2S)-2-[(\{4-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]phenyl\}carbonyl)amino]-4-(2H-tetrazol-5-yl)butanoic acid 0
                    (2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol 0
                    (3R,4R)-1-[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-4-(hydroxymethyl)pyrrolidin-3-ol 0
                    (3R,4S)-1-[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-4-[(cyclohexylthio)methyl]pyrrolidin-3-ol 0
                    (3R,4S)-1-[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-4-[(methylsulfanyl)methyl]pyrrolidin-3-ol 0
                    (3S,4R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-[(methylsulfanyl)methyl]pyrrolidine-3,4-diol 0
                    1-\{4-[4-amino-5-(3-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]benzyl\}piperidin-4-ol 0
                    2-(1,3-dimethyl-2,4,6-trioxo-5,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)-N-(2-methoxyphenyl)acetamide 0
                    2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1-pyrazolyl]-3-azetidinyl]acetonitrile 0
                    2-[[2-(2-ethyl-1-piperidinyl)-2-oxoethyl]thio]-3-methyl-5H-pyrimido[5,4-b]indol-4-one 0
                    2-amino-3,5-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 0
                    2-amino-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one 0
                    3,4-dihydroxy-2-[(methylsulfanyl)methyl]-5-(4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-7-yl)pyrrolidinium 0
                    3-[(2-fluorophenyl)methyl]-5-methyl-4-thieno[3,4]pyrrolo[1,3-d]pyrimidinone 0
                    3-[(4-fluorophenyl)methyl]-5-methyl-4-thieno[3,4]pyrrolo[1,3-d]pyrimidinone 0
                    3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1-pyrazolyl]propanenitrile 0
                    3-hydroxy-4-hydroxymethyl-1-(4-oxo-4,4a,5,7a-tetrahydro-3H-pyrrolo[3,2-d]pyrimidin-7-ylmethyl)pyrrolidinium 0
                    5-(5-chloro-1H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine 0
                    6-\{4-[(4-ethylpiperazin-1-yl)methyl]phenyl\}-N-[(1R)-1-phenylethyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine 0
                    7-aminomethyl-7-deazaguanine 0
                    7-carboxy-7-deazaguanine + 0
                    7-cyano-7-deazaguanine 0
                    7-formamidino-7-deazaguanine + 0
                    7-pyridin-2-yl-N-(3,4,5-trimethoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine 0
                    9-deazahypoxanthine 0
                    GSK2656157 3
                    LSM-16748 0
                    LSM-17257 0
                    LSM-18936 0
                    LSM-24201 0
                    LSM-32669 0
                    LSM-33192 0
                    N-(\{4-[2-(2-amino-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]phenyl\}carbonyl)-L-glutamic acid 0
                    N-(\{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]phenyl\}carbonyl)-L-glutamic acid 0
                    N-(\{4-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]phenyl\}carbonyl)-L-gamma-glutamyl-L-gamma-glutamyl-L-gamma-glutamylglutamic acid 0
                    N-(\{4-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]phenyl\}carbonyl)-L-valine 0
                    N-glycosylpyrrolopyrimidine + 16
                    PF-956980 4
                    [(2R,3R,4S,5S)-5-(2-amino-4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-7-yl)-3,4-dihydroxypyrrolidin-2-yl]methyl dihydrogen phosphate 0
                    antalarmin 6
                    batzelladine A 0
                    batzelladine B 0
                    epoxyqueuine 0
                    immucillin G 0
                    immucillin H 0
                    mirodenafil 0
                    pemetrexed 36
                    pevonedistat 35
                    queuine + 0
                    ruxolitinib + 0
                    tofacitinib + 80
                    vibegron 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 19816
    subatomic particle 19814
      composite particle 19814
        hadron 19814
          baryon 19814
            nucleon 19814
              atomic nucleus 19814
                atom 19814
                  main group element atom 19702
                    p-block element atom 19702
                      p-block molecular entity 19702
                        carbon group molecular entity 19608
                          organic molecular entity 19597
                            organic molecule 19522
                              organic cyclic compound 19320
                                organic heterocyclic compound 18432
                                  organic heteropolycyclic compound 17844
                                    organic heterobicyclic compound 16765
                                      pyrrolopyrimidine 166
                                        ((2S,3aS,4R,6S)-4-(hydroxymethyl)-6-(4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-7-yl)tetrahydrofuro[3,4-d][1,3]dioxol-2-yl)methylphosphonic acid 0
                                        (1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol 5-phosphate 0
                                        (2R)-1-[(5,6-diphenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]propan-2-ol 0
                                        (2R)-3-\{[(4Z)-5,6-diphenyl-6,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-ylidene]amino\}propane-1,2-diol 0
                                        (2S)-1-[(8aR)-hexahydropyrrolo[1,2-a]pyrimidin-1(2H)-yl]-4-methylpentan-2-amine 0
                                        (2S)-2-[(\{4-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]phenyl\}carbonyl)amino]-4-(2H-tetrazol-5-yl)butanoic acid 0
                                        (2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol 0
                                        (3R,4R)-1-[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-4-(hydroxymethyl)pyrrolidin-3-ol 0
                                        (3R,4S)-1-[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-4-[(cyclohexylthio)methyl]pyrrolidin-3-ol 0
                                        (3R,4S)-1-[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-4-[(methylsulfanyl)methyl]pyrrolidin-3-ol 0
                                        (3S,4R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-[(methylsulfanyl)methyl]pyrrolidine-3,4-diol 0
                                        1-\{4-[4-amino-5-(3-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]benzyl\}piperidin-4-ol 0
                                        2-(1,3-dimethyl-2,4,6-trioxo-5,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)-N-(2-methoxyphenyl)acetamide 0
                                        2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1-pyrazolyl]-3-azetidinyl]acetonitrile 0
                                        2-[[2-(2-ethyl-1-piperidinyl)-2-oxoethyl]thio]-3-methyl-5H-pyrimido[5,4-b]indol-4-one 0
                                        2-amino-3,5-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 0
                                        2-amino-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one 0
                                        3,4-dihydroxy-2-[(methylsulfanyl)methyl]-5-(4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-7-yl)pyrrolidinium 0
                                        3-[(2-fluorophenyl)methyl]-5-methyl-4-thieno[3,4]pyrrolo[1,3-d]pyrimidinone 0
                                        3-[(4-fluorophenyl)methyl]-5-methyl-4-thieno[3,4]pyrrolo[1,3-d]pyrimidinone 0
                                        3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1-pyrazolyl]propanenitrile 0
                                        3-hydroxy-4-hydroxymethyl-1-(4-oxo-4,4a,5,7a-tetrahydro-3H-pyrrolo[3,2-d]pyrimidin-7-ylmethyl)pyrrolidinium 0
                                        5-(5-chloro-1H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine 0
                                        6-\{4-[(4-ethylpiperazin-1-yl)methyl]phenyl\}-N-[(1R)-1-phenylethyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine 0
                                        7-aminomethyl-7-deazaguanine 0
                                        7-carboxy-7-deazaguanine + 0
                                        7-cyano-7-deazaguanine 0
                                        7-formamidino-7-deazaguanine + 0
                                        7-pyridin-2-yl-N-(3,4,5-trimethoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine 0
                                        9-deazahypoxanthine 0
                                        GSK2656157 3
                                        LSM-16748 0
                                        LSM-17257 0
                                        LSM-18936 0
                                        LSM-24201 0
                                        LSM-32669 0
                                        LSM-33192 0
                                        N-(\{4-[2-(2-amino-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]phenyl\}carbonyl)-L-glutamic acid 0
                                        N-(\{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]phenyl\}carbonyl)-L-glutamic acid 0
                                        N-(\{4-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]phenyl\}carbonyl)-L-gamma-glutamyl-L-gamma-glutamyl-L-gamma-glutamylglutamic acid 0
                                        N-(\{4-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]phenyl\}carbonyl)-L-valine 0
                                        N-glycosylpyrrolopyrimidine + 16
                                        PF-956980 4
                                        [(2R,3R,4S,5S)-5-(2-amino-4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-7-yl)-3,4-dihydroxypyrrolidin-2-yl]methyl dihydrogen phosphate 0
                                        antalarmin 6
                                        batzelladine A 0
                                        batzelladine B 0
                                        epoxyqueuine 0
                                        immucillin G 0
                                        immucillin H 0
                                        mirodenafil 0
                                        pemetrexed 36
                                        pevonedistat 35
                                        queuine + 0
                                        ruxolitinib + 0
                                        tofacitinib + 80
                                        vibegron 0
paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.